The AJMC® HIV compendium is a comprehensive resource for clinical news and expert insights for the condition, including disparities in care, prevention of infection among at-risk groups, and the importance of viral suppression.
March 12th 2025
Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a combination antiretroviral therapy (ART) in its long-acting injectable form.
This Week in Managed Care: November 30, 2018
November 30th 2018This week, the top managed care news included a CMS plan for changes in drug coverage that brought a wave of criticism; a government task force recommended more people at risk for HIV take pre-exposure prophylaxis, known as PrEP; the American College of Cardiology issued an Expert Consensus Pathway on treatment of patients with type 2 diabetes and atherosclerotic cardiovascular disease.
Watch
USPSTF Recommends Clinicians Prescribe HIV PrEP to All High-Risk Patients
November 22nd 2018The US Preventive Services Task Force (USPSTF) is recommending that clinicians offer the treatment to people at high risk of HIV, which will likely increase access to the treatment for those who need it most.
Read More
Cellular Proliferation Drives HIV Persistence During Treatment With ART
November 21st 2018According to a new study, cellular proliferation generates the majority of infected cells during antiretroviral therapy (ART), suggesting that reducing proliferation can decrease the size of the HIV reservoir and work toward a cure.
Read More
Provider Stigma Toward HIV Slows Prevention Goals
November 15th 2018As physicians have an essential role in the fight against HIV—leading patients through the care continuum—understanding HIV-related stigma among physicians can inform development of interventions to reduce this stigma and promote positive clinical outcomes.
Read More
Hispanics Living With HIV at Increased Risk of HPV-Related Cancers
November 6th 2018Hispanics living with HIV are at an increased risk of developing cancers caused by the human papillomavirus (HPV) compared to the general Hispanic population, and among people living with HIV, Hispanics are more likely to be diagnosed with cervical and penile cancer.
Read More
Researchers Propose Adding Viral Suppression Within 3 Months of HIV Diagnosis to HIV/AIDS Strategy
November 1st 2018Recognizing a need for an outcome indicator for those newly diagnosed with HIV, researchers have proposed including the percentage of newly diagnosed persons achieving viral suppression within 3 months of diagnosis.
Read More
Janssen Releases Long-Term AMBER Trial Data Supporting Safety, Efficacy of Symtuza for HIV
October 30th 2018Building on positive 48-week data, Janssen released 96-week data demonstrating high rates of virogolic suppression and tolerability among antiretroviral therapy-naïve adults with HIV-1.
Read More
Retention in HIV Care Decreases Over Time Following Release From Incarceration
October 26th 2018Following more than 1000 people living with HIV who were recently incarcerated, researchers observed that retention in care diminished significantly over time, but it was associated with HIV care during incarceration, health insurance, case management services, and early linkage to care post release.
Read More
Symtuza Achieves, Maintains Viral Suppression in Patients With HIV
October 9th 2018Treatment with Symtuza (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg) results in and maintains high virologic suppression rates, according to study findings presented at the 2018 Infectious Disease Week conference held in San Francisco, California.
Read More
Collaborative, Multidisciplinary Care Has Positive Impact on Viral Suppression in HIV
October 3rd 2018Two studies presented at the 2018 Infectious Disease Week conference held in San Francisco, California, add to a pile of research demonstrating the positive impact of collaborative, multidisciplinary care in the HIV population, specifically on viral suppression.
Read More
Unstable Housing Has Adverse Impact on Viral Suppression, CD4 Cell Count in HIV Population
September 24th 2018Unstable housing among the HIV population is associated with decreased probability of viral suppression and adequate CD4 cell count. It also lowers the likelihood of mental health/counseling, visiting a healthcare provider, and engaging in continuity of care.
Read More
This Week in Managed Care: September 21, 2018
September 21st 2018This week, the top managed care news included the Senate overwhelmingly voting to ban pharmacist gag clauses; a study found the current vaccine pipeline for HIV, tuberculosis, and malaria may fall short; an expert noted a trend of healthcare cost data seeping into nonhealthcare companies’ earnings calls.
Watch
More Than 25% of HIV Providers Don't Know If Their State Expanded Medicaid
September 20th 2018A survey has revealed gaps in HIV providers’ knowledge of the Affordable Care Act. However, despite these gaps, the majority of surveyed providers expressed belief that Medicaid expansion would improve both HIV outcomes and general outcomes for patients with the disease.
Read More
Launch of Highly Efficacious HIV, Tuberculosis, and Malaria Vaccines Unlikely, Study Says
September 18th 2018Researchers determined that the current drug pipeline is unlikely to produce any highly effective vaccines for HIV, tuberculosis, or malaria, which could be important for controlling the spread of these diseases.
Read More
Medication Adherence Program for HIV Needs Collaboration Among Physicians, Nurses, and Pharmacists
September 15th 2018A descriptive, observational study in Switzerland implemented an interprofessional medication adherence program (IMAP) in patients with HIV. The framework for the implementation of services in pharmacy (FISpH) model is described and formulated for other healthcare facilities and professionals to evaluate and execute for themselves.
Read More